Evidence map›Paper›PMID 34800265›Full record

ArticleEndocrine2022

Can ultrasensitive thyroglobulin immunoassays avoid the need for ultrasound in thyroid cancer follow-up?

Simona Censi, Antonio De Rosa, Francesca Galuppini, Jacopo Manso, Loris Bertazza, Isabella Merante-Boschin, Mario Plebani, Diego Faggian, Gianmaria Pennelli, Susi Barollo and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Simona Censi *Endocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Antonio De Rosa *Department of Oncology, Veneto Institute of Oncology IOV IRCCS, Padua, Italy.
Francesca GaluppiniSurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Jacopo MansoEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Loris BertazzaEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Isabella Merante-BoschinEndocrine Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
Mario PlebaniLaboratory Medicine, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Diego FaggianLaboratory Medicine, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Gianmaria PennelliSurgical Pathology and Cytopathology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Susi BarolloEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy.
Federica VianelloDepartment of Radiotherapy, Veneto Institute of Oncology IOV IRCCS, Padua, Italy.
Maurizio IacoboneEndocrine Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
Caterina MianEndocrinology Unit, Department of Medicine (DIMED), University of Padua, Padua, Italy. caterina.mian@unipd.it.ORCID http://orcid.org/0000-0003-2615-8001
University of Padua · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDifferentiated thyroid cancer (DTC) is the most common endocrine neoplasm, with a rising incidence and a long life expectancy. It has recently been suggested that patients with low- and intermediate-risk DTC with a good response to treatment at one year could be followed up using only highly sensitive immunoassays for thyroglobulin (Tg). The aim of this study was to examine the serum Tg levels in a series of DTC patients with histologically proven persistent or recurrent diseases.

methodsThe study involved 50 consecutive patients being routinely followed up at our center, whose clinical, histological, and biochemical data were retrospectively collected.

resultsThe false-negative rate of ultrasensitive serum Tg assay was 14.3% (5/35) overall, and limited to anti-thyroglobulin autoantibodies (TgAb)-negative patients. Among them, only one patient had an excellent response to treatment at one-year follow-up and was diagnosed with a 4 mm recurrence, after more than seven years of periodic ultrasounds. The size of the neck lesion documented in the histological report was slightly larger in patients with detectable as opposed to negative Tg values (P < 0.05).

conclusionsSerum highly sensitive Tg is undetectable in a proportion of patients with a proven persistent or recurrent DTC. The reasons behind this phenomenon are still unknown. However, in low/intermediate-risk patients cured at one-year follow-up, highly sensitive Tg without neck US seems an appropriate strategy for patients' management.

Indexed as

ThyroglobulinThyroid NeoplasmsAutoantibodiesFollow-Up StudiesHumansImmunoassayNeoplasm Recurrence, LocalRetrospective Studiesanti-thyroid autoantibodiesAutoantibodiesThyroglobulinDifferentiated thyroid cancerFollow-upThyroglobulin

Identifiers

PMID34800265
OpenAlexW3212260830

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.